Infiltrating Bladder Urothelial Carcinoma

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

199 sites for NCT03682068

Urothelial Carcinoma

carboplatin, +4 more drugs

chemotherapy, +1 more type

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin

194 sites for NCT04960709

Bladder Urothelial Carcinoma

durvalumab, +3 more drugs

chemotherapy, +3 more types

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

94 sites for NCT04700124

Bladder Carcinoma, +1 more condition

cisplatin, +4 more drugs

chemotherapy, +3 more types

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

245 sites for NCT04637594

Bladder Urothelial Carcinoma, +4 more conditions

atezolizumab, +4 more drugs

immunotherapy

Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

154 sites for NCT04165317

Bladder Urothelial Carcinoma, +2 more conditions

BCG solution, +1 more drug

immunotherapy

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

131 sites for NCT03711032

Bladder Urothelial Carcinoma

BCG solution, +1 more drug

immunotherapy

Show 189 Trials for Infiltrating Bladder Urothelial Carcinoma

erdafitinib